Stay updated with breaking news from Robert Bissonnette. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An investigational IL-23R antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe psoriasis compared with placebo at week 16 in the FRONTIER 1 study.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial...
New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.
– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 ... | May 1, 2023
The phase 3 study evaluated delgocitinib, an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway and targets key mediators of chronic hand eczema.